ÈÖ¹æ |
ɽÂê |
Í×Ìó |
ÂоݼÔÅù |
·ÇºÜ»ïÅù |
117 |
¥á¥ê¥Ã¥µÃê½Ð±ÕBG-JÇÛ¹çÀ½ºÞ¤ÎÅÉÉۤˤè¤ëÈéÉæ¤Î¥·¥ï²þÁ±¸ú²Ì¤Îɾ²Á |
Background:
The collagen receptor Endo180 participates in extracellular matrix remodeling by clearing the pericellular envi
ronment and recognizing and internalizing collagen degradation products. In photoaged skin, Endo180 expression in fibroblasts is decreased, and collagen fragments accumulate in the pericellular environment, leading to a decrease in type I collagen production and an increase in matrix metalloproteinase 1 production. This suggests that a decrease in Endo180 production may promote wrinkle formation by decreasing the dermal collagen fibril volume. Therefore, this study aimed to identify materials that promote Endo180 production in vitro and investigate whether promoting Endo180 production could prevent and improve wrinkles in vivo.
Methods:
Endo180 gene expression and protein production in fibroblasts were evaluated after screening 71 natural extracts. The conditioned medium of UVB- irradiated keratinocytes and Endo180 production- promoting extract were added to fibroblasts, and Endo180 and type I collagen production were evaluated. In a double- blind, randomized, placebo- controlled study, a cream formulated with an Endo180 production- promoting extract or placebo was topically administered to each side of the face of 20 healthy women twice daily for 8 weeks.
Results:
Screening results showed that 50 ¦Ìg/mL of lemon balm (Melissa officinalis L.) leaf extract (MOLE) resulted in the highest levels of both Endo180 mRNA and protein at 178.1% and 127.4%, respectively. Its major component rosmarinic acid also promoted Endo180 production by 143.9% at a concentration of 20 ¦Ìg/mL. MOLE at 200 ¦Ìg/mL almost completely inhibited the decrease in Endo180 and type I collagen production in UVB- irradiated keratinocyte- conditioned medium. Furthermore, eyecorner wrinkles were reduced by treatment with the MOLE¡¡formulation compared to that in response to the placebo formulation.
Conclusions:
MOLE may act as an antiwrinkle agent that inhibits the decline in collagen levels by promoting Endo180¡¡production. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
116 |
À֥֥ɥ¦ÍÕ´ÞÍ¿©ÉʤÎÀݼè¤Ë¤è¤ë²¼»è¤à¤¯¤ß·Ú¸º¸ú²Ì¤Îɾ²Á |
²¼»è¤à¤¯¤ß¤ò¼«³Ð¤¹¤ë30¡¡ºÐ°Ê¾å60¡¡ºÐ°Ê²¼¤Î½÷À¤òÂоݤË5¡¡»þ´ÖϢ³¤Ç¤ÎºÂ°Ì»ÑÀª¤ò°Ý»ý¤µ¤»¤ëÉé²Ù¤Ë¤è¤ë¿Í¹©Åª¤Ê²¼»è¤à¤¯¤ß¤ËÂФ·¤Æ¡¤À֥֥ɥ¦ÍÕ´ÞÍ¿©Éʤò4¡¡½µ´ÖϢ³Àݼ褷¤¿ºÝ¤Îº¸±¦¤Õ¤¯¤é¤Ï¤®¼þ°ÏŤÎÊѲ½¤òɾ²Á¤·¤¿¡£¤½¤Î·ë²Ì¡¤ÀݼèÁ°´Ñ»¡»þ¤ÎºÂ°Ì»ÑÀª¤ò°Ý»ý¤µ¤»¤ëÉé²Ù¤ÈÈæ³Ó¤·¡¤Àݼè4¡¡½µ¸å¤Ë¤ª¤¤¤ÆÀäÂÐÃÍɾ²Á¤ª¤è¤Óº¹Ê¬ÃÍɾ²Á¤Ë¤ª¤±¤ëÉé²Ù3¡¡»þ´Ö¸å¤Î±¦¤Õ¤¯¤é¤Ï¤®¼þ°ÏĹ¡¤¤Þ¤¿ÁêÂÐÃÍɾ²Á¤Ë¤ª¤±¤ëÉé²Ù1¡¡»þ´Ö¸å¤Çº¸¤Õ¤¯¤é¤Ï¤®¼þ°ÏŤ¬Í°Õ¤Ë²þÁ±¤·¤¿¡£¤³¤Î¤³¤È¤«¤é¡¤È︳ÉʤηѳÀݼè¤Ë¤è¤ê¡¤²¼»è¤Î¤à¤¯¤ß¤Î·Ú¸º¤¬´üÂԤǤ¤ë¤È¹Í¤¨¤é¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
115 |
A Randomized, Comparative Study of Skin Adhesion Between CATHEREEPLUS Pad and Tegaderm Pad Film Dressings in Healthy Participants |
¡ãObjective¡ä
This study aimed to compare the adhesion of CATHEREEPLUSTM Pad (CPSP; NICHIBAN Co., Ltd., Tokyo, Japan) and TegadermTM +Pad (TGMP; 3M, Maplewood, MN, USA) film dressings on the forearm skin of healthy participants over a four-day application period.
¡ãMethods¡ä
Twenty-six randomly assigned participants received CPSP dressing on one arm and TGMP on the other. The primary endpoint was adhesion to the skin after four days of dermal application. Secondary endpoints were adhesion and itchiness during the application period, pain experienced during dressing removal, skin maceration, adhesive residue immediately post-dressing removal, and skin reactions at one and 24 hours post-dressing removal. All endpoints were evaluated using a five- or six-point scoring system.
¡ãResults¡ä
Following four days of dressing application, 77% of participants in the CPSP group and 73% of those in the TGMP group scored 4 (most) or 5 (complete) for adhesion. No clinically significant problems such as itchiness, pain, skin maceration, adhesive residue, or skin reactions were observed in either group. No statistically significant differences in any of the endpoints were observed between the two groups.
¡ãConclusion¡ä
Both CPSP and TGMP dressings showed good adhesion to the skin during four days of dermal application in healthy participants, with no significant difference in adhesion observed between the two groups |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
114 |
Effects of Lactoferrin on Oral and Throat Conditions under Low Humidity Environments: A Randomized, Double-Blind, and Placebo-Controlled Crossover Tria |
To evaluate the effects of a single ingestion of bovine lactoferrin (bLF) on oral and throat conditions under a low-humidity environment. A randomized, double-blind, 2-sequence, 2-treatment, and 2-period placebo-controlled crossover trial was conducted. Healthy adult subjects orally ingested bLF dissolved in water, or placebo water, followed by exposure to low humidity (20 ◦C, 20% relative humidity (RH)) for 2 h. The primary endpoint was subjective oral and throat discomfort assessed by a visual analog scale (VAS), which positively correlated with the discomfort. Secondary endpoints were unstimulated whole salivary flow rate (UWSFR) and salivary immunoglobulin A (IgA) secretion rate. Overall, 40 subjects were randomly assigned to two sequences (20 each) and 34 were analyzed.
The VAS values for oral and throat discomfort in the bLF treatment were significantly lower than in the placebo treatment, whereas UWSFR and IgA secretion rates were comparable between the two treatments. Adverse drug reactions were not observed. Subjective oral and throat discomfort associated with low humidity is suppressed by a single ingestion of bLF. Our findings demonstrate the novel use of bLF in a clinical situation that leverages its unique characteristics. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
113 |
¥·¥ã¥ó¥×¡¼¤ª¤è¤Ó¥¹¥«¥ë¥×¥¨¥Ã¥»¥ó¥¹¤Î»ÈÍѤˤè¤ëƬȱ¤Ø¤Î¸ú²Ì¤Îɾ²Á |
¥·¥ã¥ó¥×¡¼¤ÈƬÈ饨¥Ã¥»¥ó¥¹¤Î»ÈÍÑÁ°¸å¤Ç¡¢µÒ´Ñɾ²Á¤È¤·¤ÆÌÓȱ·Â¤ª¤è¤ÓÌÓȱËÜ¿ô¤Î²òÀÏ¡¤¤Þ¤¿Àöȱ»þ¤ÎÈ´¤±ÌÓËÜ¿ô¤Î²òÀÏ¡¤¼ç´Ñɾ²Á¤È¤·¤Æ¥¢¥ó¥±¡¼¥È¤òÀßÄꤷɾ²Á¤ò¹Ô¤Ã¤¿¡£»î¸³À½Éʤϡ¢30ºÐ¤«¤é59ºÐ¤Þ¤Ç¤Î39¿Í¤Î·ò¹¯¤ÊÆüËÜ¿ÍÃ˽÷¤Ë24½µ´Ö»ÈÍѤȤ·¤¿¡£»ÈÍѸ塢ȱ¤ÎËÜ¿ô¡¢ÌÓȱ¤Îľ·Â¡¢¤ª¤è¤Ó¼ç´Ñɾ²Á¤¬Í°Õ¤Ë²þÁ±¤µ¤ì¤¿¡£¤³¤ì¤Ë¤è¤ê¡¢»î¸³À½ÉʤλÈÍѤ¬ÇöÌÓ¤äÈ´¤±ÌÓ¤Ë͸ú¤Ç¤¢¤ë¤³¤È¤¬¼¨º¶¤µ¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
112 |
Effects of high-fiber food product consumption and personal health record¡¡use on body mass index and bowel movemen |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
111 |
Ç¥ÉØ¤ËÂФ¹¤ë¥Ü¥Ç¥£ÍÑ¥¯¥ê¡¼¥à¤Î°ÂÁ´À¤ª¤è¤ÓÍÍÑÀ¤Î¸¡Æ¤ |
»î¸³³«»Ï»þ¤ÎÇ¥¿±½µ¿ô¤¬9¡Á32½µ¤ÎÇ¥ÉØ31̾¤òÂоݤˡ¢Ê¢Éô¤ËÊݼ¾¥¯¥ê¡¼¥à¤ò4½µ´ÖÏ¢ÁÛ¤µ¤»¤¿¤È¤³¤í¡¢³«»Ï»þ¤ÈÈæ³Ó¤·¡¢ÈéÉæ½ê¸«¤Î´¥Á祹¥³¥¢¤¬Í¥°Ì¤ËÄã²¼¤·¤¿¡£µ¡´ï¬Äê¤Ë¤ª¤¤¤Æ¤ÏÈéÉæ¿åʬÎ̬Äê¡¢Èé»éÎÌ¡¢ÈéÉæÃÆÎÏÀ¡¢ÈéÉæÌ©ÅÙ¡¢¿¿ÈéÌ©ÅÙ¤ª¤è¤ÓɽÈéÌ©ÅÙ¤ÎͰդÊÁý²Ã¤¬¤ß¤é¤ì¤¿¡£¤Þ¤¿¡¢Í³²»ö¾Ý¤Ï1Îã¤â¤Ê¤¯Ëܻ¤Ç»ÈÍѤ·¤¿Êݼ¾¥¯¥ê¡¼¥à¤Ï°ÂÁ´À¤¬¹â¤¤¤³¤È¤¬³Îǧ¤µ¤ì¤¿¡£¤³¤ì¤é¤Î¤³¤È¤è¤ê¡¢Ç¥¿±Ãæ¤Ë¹â¤¤Êݼ¾ÎϤòͤ¹¤ë¥Ü¥Ç¥£ÍÑ¥¯¥ê¡¼¥à¤ò·Ñ³¤·¤Æ»ÈÍѤ¹¤ë¤³¤È¤Ï¡¢Ç¥ÉؤÎÈéÉæ¤ò·ò¤ä¤«¤ËÊݤĤ¿¤á¤ËÍÍѤǤ¢¤ë¤È¹Í¤¨¤é¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
110 |
¥Ö¥é¥··¿ÈþÍÆµ¡´ï¤Î»ÈÍѤˤè¤ëµÓ¤Î·ìή²þÁ±¤Îɾ²Á |
20 ºÐ°Ê¾å60 ºÐ°Ê²¼¤Î½÷À¤òÂоݤˡ¤Äã¼þÇÈÈþÍÆµ¡´ï¤òñ²ó»ÈÍѤ·¤¿ºÝ¤ÎµÓ¤Î·ìή¤ÎÊѲ½¤òɾ²Á¤·¤¿¡£¤½¤Î·ë²Ì¡¤±¦¤Õ¤È¤â¤â΢¤ÎÊ¿¶Ñ·ìήÎ̤¬Í°Õ¤Ë²þÁ±¤·¤¿¡£¤³¤Î¤³¤È¤«¤é¡¤È︳ÉʤλÈÍѤˤè¤ê¡¤µÓ¤Î·ì¹Ô¤¬Â¥¿Ê¤µ¤ì¡¤¤à¤¯¤ß¤Î·Ú¸º¤¬´üÂԤǤ¤ë¤È¹Í¤¨¤é¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
109 |
ÊØÈë¤òÁʤ¨¤ëÀ®¿Í½÷À¤òÂоݤȤ·¤¿·¬¤ÎÍÕÀĽÁÀݼè¤Ë¤è¤ëIJÆâ´Ä¶¤ª¤è¤ÓÈéÉæµ¡Ç½¤ËµÚ¤Ü¤¹±Æ¶Á |
ÊØÈë¤ÏIJÆâ´Ä¶¤Î°²½¤À¤±¤Ç¤Ï¤Ê¤¯¡¢ÍÍ¡¹¤Ê¼À´µ¤äÈéÉæµ¡Ç½¤Ë¤â±Æ¶Á¤òÍ¿¤¨¤ë¤³¤È¤«¤é¡¢ÊØÈë²þÁ±¤äIJÆâ´Ä¶²þÁ±¤Ø¤Î´Ø¿´¤¬¹â¤Þ¤Ã¤Æ¤¤¤ë¡£Ëܸ¦µæ¤Ç¤ÏÊØÈë¤òÁʤ¨¤ëÀ®¿Í½÷À¤Ë¡¢·¬¤ÎÍÕÊ´Ëö¤ò¼çÀ®Ê¬¤È¤·¤¿·¬¤ÎÍÕÀĽÁ¤ò1Æü3²ó¡¢2¤«·î·Ñ³Àݼ褵¤»¤¿¡£·¬¤ÎÍÕÀĽÁÀݼèÁ°¸å¤ÎIJÆâ´Ä¶¤òÈæ³Ó¤·¤¿·ë²Ì¡¢ÇÓÊØ²ó¿ô¤¬Í°Õ¤ËÁý²Ã¤·¡¢Ä²ÆâºÙ¶ÝÁѤÎBifudobacterium¤ÈLactobacillales¤ÎÀêÍΨ¤¬Í°Õ¤ËÁý²Ã¤·¤¿¡£ÈéÉæµ¡Ç½¤Ë¤ª¤¤¤Æ¤Ï¡¢ÈéÉæÃÆÎÏÀ¤¬Í°Õ¤ËÁý²Ã¤·¤¿¡£°Ê¾å¤Î·ë²Ì¤è¤ê¡¢·¬¤ÎÍÕÀĽÁ¤ÎÀݼè¤ÏÎɹ¥¤Ê±Æ¶Á¤òµÚ¤Ü¤¹¤³¤È¤¬¼¨º¶¤µ¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
108 |
¥Ò¥·¥¨¥¥¹¤ª¤è¤Ó¥È¥Þ¥ÈÃê½Ðʪ´ÞÍ¥µ¥×¥ê¥á¥ó¥È¤ÎÀݼè¤Ë¤è¤ëÈ©¤ÎÊݼ¾À¡¤¹³Åü²½¡¤¹³¥«¥ë¥Ü¥Ë¥ë²½¤Ê¤é¤Ó¤Ë¹³»À²½¤Ë´Ø¤¹¤ëÎ×¾²»î¸³ |
Ëܻ¤Ç¤Ï¡¤20 ºÐ°Ê¾å 64 ºÐ°Ê²¼¤ÎÁ´¿È¤ÎÈéÉæ¤Î´¥Á硤ÈéÉæ¤Î¤¿¤ë¤ß¤ò¼«³Ð¤¹¤ë·ò¾ï¿ÍÃ˽÷¤òÂоݤȤ·¤Æ¡¤ÈéÉæ¿åʬ¾ø»¶Î̤ò»ØÉ¸¤È¤·¤¿Êݼ¾À¸þ¾å¤Ë¤è¤ë¥Ð¥ê¥¢µ¡Ç½²þÁ±¡¤¿§º¹·×¤äÈ©¾õÂÖ»£±Æ¤ò¤Ï¤¸¤á¤È¤¹¤ëÈ©¿§¤Ø¤Î±Æ¶Á¡¤AGEs ÃͤäÅü»À²½Êª¼Á¤ò»ØÉ¸¤È¤¹¤ë¹³Åü²½¡¤¹³¥«¥ë¥Ü¥Ë¥ë²½¡¤¹³»À²½¤ÎºîÍѤˤĤ¤¤Æ³Îǧ¤¹¤ë¤³¤È¤òÌÜŪ¤È¤·¤Æ¡¤¥Ò¥·¥¨¥¥¹¤ª¤è¤Ó¥È¥Þ¥ÈÃê½Ðʪ¤Î 12 ½µ´ÖϢ³Àݼè¤Ë¤è¤ë̵ºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó»î¸³¤ò¼Â»Ü¤·¤¿¡£
¡¡ÈéÉæ¿åʬ¾ø»¶ÎÌÄã²¼¤Ë¤è¤ëÈ©¤ÎÊݼ¾À¸þ¾å¤Ë¤è¤ëÈéÉæ¥Ð¥ê¥¢µ¡Ç½²þÁ±¸ú²Ì¡¤¿§º¹·×¤ª¤è¤ÓÈ©¾õÂÖ»£±Æ¤Ë¤è¤ëÈ©¿§¸þ¾å¸ú²Ì¤¬³Îǧ¤µ¤ì¤¿¡£¤Þ¤¿¡¤Åü²½¡¦¥«¥ë¥Ü¥Ë¥ë²½È¿±þʪ¼Á¤Ç¤¢¤ë¥Ú¥ó¥È¥·¥¸¥ó¸º¾¯¤Ë¤è¤ë¹³Åü²½ºîÍÑ¡¤¹³¥«¥ë¥Ü¥Ë¥ë²½ºîÍѤ¬Ç§¤á¤é¤ì¤¿¡£
¡¡¤µ¤é¤Ë¡¤°ÂÁ´À¤Ë´Ø¤·¤Æ¤âÉûºîÍÑ¡¤Í³²»ö¾ÝÄ´ºº¤Ë¤Ä¤¤¤Æ¡¤»î¸³´ü´ÖÃæ¤ËÌäÂê¤È¤Ê¤ë¤è¤¦¤Ê»ö¾Ý¤Ï³Îǧ¤µ¤ì¤Ê¤«¤Ã¤¿¡£
¡¡°Ê¾å¤Î¤³¤È¤«¤é¥Ò¥·¥¨¥¥¹¤ª¤è¤Ó¥È¥Þ¥ÈÃê½Ðʪ¥µ¥×¥ê¥á¥ó¥È¤ÎÀݼè¤Ë¤è¤ë¡¤¹³Åü²½ºîÍÑ¡¤¹³¥«¥ë¥Ü¥Ë¥ë²½ºîÍѤˤè¤êÈ©¿§¤ò¸þ¾å¤·ÈéÉæ¤Î¥Ð¥ê¥¢µ¡Ç½²þÁ±¡¤È©¤ÎÊݼ¾À¸þ¾å¤¬´üÂԤǤ¤ë¤³¤È¤¬ÌÀ¤é¤«¤È¤Ê¤Ã¤¿ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
107 |
¼«³ÐŪ¤Ê¸ª¤³¤ê¾É¾õ¤Ë¤ª¤±¤ë¿´Íý¾õÂÖ¤ò¤Õ¤Þ¤¨¤¿¥¨¥¾¥¦¥³¥®¿©ÉʤαƶÁ |
Objevtives This study aimed to evaluate the effects of taking Acanthopanax Harms on the subjective sympton of shoulder muscle stiffness in assocication with mental conditions.
Method A before-after comparative study without placebo was conducted in 13 japanese male and female subjects aged betwwen 20 and 59 years and who had a subjective sympton of shoulder muscle stiffness. The subjects received Acanthopanax senticosus Harms at 24 tablets daily for 4 consecutive weeks. Shoulder muscle stiffness and mood state were evaluated by VAS scores and POMS scores, respectively, at baseline and at treatment weeks 2 and 4.
Result The VAS scores of 'shoulder muscle stiffness' and 'shoulder tention'significantry decreased at treatment week 4,compared to that at baseline. In adition , the POMS scores of 'Confusion' significantry decreased at treatment week 4. A significant negative correlation was obsereved between the decreased 'shoulder muscle stiffness' score and the POMS score of ''Vigor' at treatment week 4.
Conclution we showed that taking Acanthopanax senticosus Harms improved the subjectike sympton ofshoulder muscle stiffness,with mood state improvement suggested as the underlying fector. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
106 |
¥ß¥ì¥Ã¥È¥¨¥¥¹, ¥Ñ¥ó¥È¥Æ¥ó»À¥«¥ë¥·¥¦¥à, L-¥·¥¹¥Á¥ó, ¥Ó¥ª¥Á¥ó´ÞÍ¿©ÉʤÎÀݼè¤Ë¤è¤ëÌÓȱ̩ÅÙ¤ª¤è¤ÓƬȱ¤Î³°´ÑÊѲ½¤Î¸¡¾Ú»î¸³ |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
105 |
¥¨¥¤¥³¥µ¥Ú¥ó¥¿¥¨¥ó»À¡¦¥É¥³¥µ¥Ø¥¥µ¥¨¥ó»À´Þ͵ûÌý¤ÎÀݼè¤Ë¤è¤ë¼ê»ØËö¾¿Âβ¹¤Ø¤Î±Æ¶Áɾ²Á - ¥é¥ó¥À¥à²½¥×¥é¥»¥ÜÂÐ¾ÈÆó½ÅÌÕ¸¡Ê¹Է²´ÖÈæ³Ó»î¸³ - |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
104 |
Ç»½Ì¹È¹í¥«¥×¥»¥ë¤ÎÀݼè¤Ë¤è¤ë¥³¥ì¥¹¥Æ¥í¡¼¥ëÄ´Àá¸ú²Ì¤Îɾ²Á - ̵ºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó»î¸³ - |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
103 |
¡Ö¥é¥¯¥È¥È¥ê¥Ú¥×¥Á¥É (VPP, IPP)¡×¤ò´Þͤ¹¤ë¥¿¥Ö¥ì¥Ã¥È¤ÎÀݼ褬·ò¾ï¼ãǯ¼Ô¤ÎÈèÏ«´¶¤ËµÚ¤Ü¤¹±Æ¶Á - ¥é¥ó¥À¥à²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó»î¸³ - |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
102 |
¥Ò¥Ï¥ÄÃê½Ðʪ¤Î·ì°µ¤ËÂФ¹¤ëõº÷Ū¸¡Æ¤ |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
101 |
¥Ò¥Ï¥ÄÃê½Ðʪ´ÞÍÊ´ËöÎÐÃã¤Î²á¾êÀݼè»þ¤Î°ÂÁ´À¤Î¸¡Æ¤ |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
100 |
ÊÆæõ²ê¥¨¥¥¹ÇÛ¹çÊ´Ëöðùγ¤ÎÀݼè¤Ë¤è¤ëÁ´¿È¤ÎÈéÉæ¥Ð¥ê¥¢µ¡Ç½¤ËÂФ¹¤ë²þÁ±¸ú²Ì |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
99 |
¾®»ù¤Ë¤ª¤±¤ë¥°¥í¥Ó¥óÃÁÇòʬ²òʪÇÛ¹ç¡Ö¥Ê¥Ã¥×¥ë(R)GD¡×12½µ´ÖÀݼè¤Î°ÂÁ´Àɾ²Á |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
98 |
ËÜÂÖÀ¹â·ì°µ¾É¤Î¼£ÎŤˤª¤±¤ë¸åȯ°åÌôÉʤÎÎ×¾²Åª¸¡Æ¤-¥¢¥à¥í¥¸¥Ô¥óOD¾û¡Ö¥±¥ß¥Õ¥¡¡×¤ÎÍÍÑÀ- |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
97 |
¥«¥Ä¥ª¥¨¥é¥¹¥Á¥ó´ÞÍ¥µ¥×¥ê¥á¥ó¥È¤Î¥Ò¥ÈÈ©¤ËÂФ¹¤ëÍÍÑÀ¸¡Æ¤ |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
96 |
Clinical Utility of Erythrocyte Sedimentation Rate Test |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
95 |
2·¿ÅüǢɴµ¼Ô¤Ë¤ª¤±¤ë¥Ô¥ª¥°¥ê¥¿¥¾¥ó¾û15mg¡Ö¥µ¥ï¥¤¡×¤ÎÎ×¾²ÅªÍÍÑÀ¤Î¸¡Æ¤ ¡½¥¢¥¯¥È¥¹(R)¾û15¤È¤ÎʹԷ²´ÖÈæ³Ó»î¸³¡½ |
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
94 |
Lactobacillus acidopilus L-92´ÞÍ¿©ÉÊÀݼè¤Ë¤è¤ë²ÖÊ´¾É;ɼԤËÂФ¹¤ë±Æ¶Á
¡½¥é¥ó¥À¥à²½¥×¥é¥»¥ÜÂÐ¾ÈÆó½ÅÌÕ¸¡Ê¹Է²´Ö»î¸³¡½ |
Objevtives Several clinical trials have reported that oral administration of Lactobacillus acidophilus L-92(L-92) alleviated allergic symptoms. We,therefor,evaluated the effect of oralingestion of tablets containing L-92 on the symptoms of cedar pollen allergy.
Methods We conducted a randomized,double-blind,placebo-controlled parallel-groupstudy. Subjects were randomly divided into two groups,one group ingested two tablets containing 20.7mg of L-92 and other group ingested placebo tablets for 12 weeks.During this period,subjects assesed their nasal and ocular symptoms every day. These symptoms were scored from 0 (no symptom) to 4 (very severe). The severity of the symptoms was evaluated based on the scores which subjects assessed by themselves. Blood samples were used to determine the concentration of non-specfic IgE,anti-cedar IgE,and anti-cypress IgE.
Results Itchy eyes score,ocular symptom score and ocular symptom-medication score of L-92 group were significantly lower compared with the placebo group. The score for sneezing tended to be improved compared with the placebo group. Anti-cypress IgE level in L-92 group was reduced compared with the placebo group in the 12-weeks period.
Conclusion These results clearly suggest that oral administration of L-92 could alleviate the symptoms of pollen allergy. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
93 |
¤³¤ó¤Ë¤ã¤¯¥»¥é¥ß¥É´ÞÍ¿©ÉʤÎÀݼè¤Ë¤è¤ëÈ©¤ÎÊݼ¾À¤ò¤Ï¤¸¤á¤È¤¹¤ëÈ©½ô¾É¾õ²þÁ±»î¸³
¡½Ìµºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó¡½ |
¤³¤ó¤Ë¤ã¤¯°òͳÍ襰¥ë¥³¥·¥ë¥»¥é¥ß¥É¡Ê¤³¤ó¤Ë¤ã¤¯¥»¥é¥ß¥É¡Ë1.8 mg ¤ò´Þ¤à¿©Éʤò¡¤12 ½µ´ÖËèÆüÀÝ¿©¤¹¤ë·ò¾ï¿Í»î¸³¤Ç¡¤ÈéÉæ¿åʬ¾ø»¶Î̤¬²þÁ±¤µ¤ì¤ëÊó¹ð¤Ï¤µ¤ì¤Æ¤¤¤ë¤¬¡¤ÄãÍÑÎ̤ǤÎÊó¹ð¤Ï¤Ê¤«¤Ã¤¿¡£¤½¤³¤Ç¡¤¤ï¤ì¤ï¤ì¤Ï¡¤¤³¤ó¤Ë¤ã¤¯¥»¥é¥ß¥É1 Æü0.6 mg¤È1.2 mg ¤òÀÝ¿©¤¹¤ë¥Ò¥È»î¸³¤ò¼Â»Ü¤·¤¿¡£¡¡35 ºÐ°Ê¾å59 ºÐ°Ê²¼¤ÎÈéÉæ¤Î´¥Á硤ȩ¹Ó¤ì¤ä¤¿¤ë¤ß¤ò¼«³Ð¤¹¤ë·ò¾ï¿ÍÃ˽÷¤òÂоݤȤ·¤Æ¡¤12 ½µ´Ö¤Î̵ºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó»î¸³¤Ë¤è¤ê¡¤È©¸¡ºº¡ÊÈéÉæ¿åʬÎÌ¡¤ÈéÉæ¿åʬ¾ø»¶ÎÌ¡¤ÈéÉæÃÆÎÏÀ¡¤ÈéÉæpH¡¤È©¿§Â¬Äꡤ³ÑÁزòÀÏ¡¤È©¾õÂÖ²òÀÏ¡¤¼«³Ð¾É¾õ¥¢¥ó¥±¡¼¥È¡¤ÈéÉæ²Ê°å¤Ë¤è¤ë½ê¸«¡Ë¤ò¹Ô¤Ã¤¿¡£
¡¡¤½¤Î·ë²Ì¡¤ÈéÉæ¿åʬ¾ø»¶Î̤κ¹Ê¬Ãͤ¬¡¤0.6 mg ÀÝ¿©·²¤Ç±¦頰Éô¤È±¦ÉªÉô¡¤¤µ¤é¤Ë1.2 mg ÀÝ¿©·²¤Ç¤Ï¡¤±¦頰Éô¤È¾åÇØÉô¡¤±¦ÂÇØÉô¤Ç¡¤¥×¥é¥»¥Ü·²¤ËÂФ·¤ÆÍ°Õ¤Ë²þÁ±¤¹¤ë¤³¤È¤¬³Îǧ¤µ¤ì¤¿¡£¤Þ¤¿¡¤¥¢¥ó¥±¡¼¥ÈÄ´ºº¤Ç¤â¡¤1.2 mg ÀÝ¿©·²¤Ç¡¤¡ÖÈ©¤Î½á¤¤¡×¤È¡ÖÈ©¤Î¥¥á¡×¤Î²þÁ±¤¬¼Â´¶¤Ç¤¤ë¤³¤È¤¬¼¨¤µ¤ì¤¿¡£¤µ¤é¤Ë¡¤°ÂÁ´À¤Ë´Ø¤·¤Æ¤âÉûºîÍÑ¡¤Í³²»ö¾ÝÄ´ºº¤Ë¤Ä¤¤¤Æ¡¤»î¸³´ü´ÖÃæ¤ËÌäÂê¤È¤Ê¤ë¤è¤¦¤Ê»ö¾Ý¤Ï³Îǧ¤µ¤ì¤Ê¤«¤Ã¤¿¡£¡¡¤³¤ó¤Ë¤ã¤¯¥»¥é¥ß¥É¤Ï¡¤1 Æü¤ÎÀÝ¿©Î̤¬0.6 mg¡¤1.2 mg ¤ÎÄãÍÑÎ̤Ǥ⡤ȩ¾õÂ֡ʥХꥢµ¡Ç½¤äÊݼ¾ºî
Íѡˤò²þÁ±¤·¡¤1.2 mg Àݼ跲¤Ç¤Ï¡¤¤½¤Î¸ú²Ì¤ò¼Â´¶¤Ç¤¤ë¤³¤È¤¬³Îǧ¤µ¤ì¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
92 |
¥³¥é¡¼¥²¥ó¥Ú¥×¥Á¥ÉÀݼè¤ÎɨÄË·Ú¸ººîÍѤȰÂÁ´À¤Îɾ²Á |
Ʊ°Õ¼èÆÀ»þ¤ÎǯÎð¤¬45ºÐ°Ê¾å70ºÐ°Ê²¼¤ÎÆüËÜ¿ÍÃËÀ¤ª¤è¤Ó½÷À¤òÂоݤË,¥é¥ó¥À¥à²½¥×¥é¥»¥ÜÂÐ¾ÈÆó½ÅÌÕ¸¡·²´ÖÈæ³Ó»î¸³¤È¤·,¸¡ºº»þ´ü¤ÏÀݼèÁ°,Àݼè4½µ¸å,8½µ¸å,12½µ¸å¤Î4²ó¤Ç,Àݼè´ü´Ö¤Ï84Æü´Ö¤È¤·¤¿¡£È︳¼Ô¤Ï56̾¤ÇËܻ¤ò³«»Ï¤·¤¿¤¬,ÅÓÃæ¤ÇÈ︳¿©ÉÊ·²3̾¤È¥×¥é¥»¥Ü¿©ÉÊ·²1̾¤¬¼«¸ÊÅÔ¹ç¤Ç¼Âष¤¿¤¿¤á,52̾¤¬²òÀÏÂоݤȤʤä¿¡£Ã˽÷Èæ,ǯÎð,¿ÈĹ,ÂνÅ,BMI,JKOM¹ç·×,JKOM VAS,KLʬÎà¤ÎÆâÌõ¤Ë¤Ï,»î¸³¿©ÉÊ·²´Ö¤Ç¤ÎͰպ¹¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¡£JKOM¤Ç¤Î¡µ¯¾²»þ¤Îɨ¤Î¤³¤ï¤Ð¤ê,¢Ê¿ÃϤǤÎɨÄË,£³¬Ãʾº¤ê»þ¤ÎɨÄË,¤Î©¤Ã¤Æ¤¤¤ë¤È¤¤ÎɨÄË,¥·ò¹¯¾õÂÖ¤È,¦·ò¹¯¾õÂ֤ؤΰ±Æ¶Á¤¬È︳¿©ÉÊ·²¤Î¤ß¤Ç²þÁ±¤·¤¿¤³¤È¤¬¼¨¤µ¤ì¤¿¡£·ë²Ì,È︳¿©ÉʤηѳŪÀݼ褬·ò¾ï¼Ô¤Îɨ¤ÎÄˤߤ䤳¤ï¤Ð¤ê¤ò·Ú¸º¤·¤ÆÉ¨¾õÂÖ¤ò²þÁ±¤·,·ò¹¯Áý¿Ê¤ËƳ¤¯²ÄǽÀ¤¬¼¨¤µ¤ì¤¿¡£°ÂÁ´À¤ÎÌ̤ǤÏ,·ì±ÕÀ¸²½³Ø¸¡ºº¤Ï,ͰդÊÊÑÆ°¤Î¤¢¤ë¹àÌܤò¤¢¤Ã¤¿¤¬,À¸ÍýŪÊÑÆ°¤ÎÈϰϤǤ¢¤Ã¤¿¡£Ç¢¸¡ºº¤Ï,¤¤¤º¤ì¤Î¹àÌܤˤâÊÑÆ°¤Ï¤Ê¤«¤Ã¤¿¡£¤Þ¤¿,ͳ²»ö¾Ý¤Ï³Îǧ¤µ¤ì¤Ê¤«¤Ã¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
91 |
·ò¾ï¼Ô¤òÂоݤȤ·¤¿Ç¾µ¡Ç½²þÁ±¤ËµÚ¤Ü¤¹¥×¥é¥º¥Þ¥í¡¼¥²¥óÀݼè¤Î±Æ¶Á¡¡¡½Ìµºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó¡½
|
To examine the effects of plasmalogen on brain function, a randomized double︱
blind placebo︱controlled parallel group comparison study was conducted with 50 to 70 years
old healty male and female who were aware of forgetfulness.
Methods¡¡Plasmalogens used in this study were prepared from chicken breast meat, and were
administered of low dose¡Ê1 mg plasmalogens╱day¡Ëto high dose¡Ê100 mg plasmalogens╱day¡Ë
for 12 weeks to subjects.
Results¡¡In Urbans neuropsychological test, significant scores were observed at the high dose
and low dose groups compared with 12 weeks after intake to before intake in the overall evaluation
item, respectively. Even in Cognitrax test, the score in some items increased significantly
compared with before to after intake. The safety of plasmalogens was confirmed, because no
adverse events were obserbed during this study.
Conclutions¡¡It can be said that plasmalogens derived from chicken beast meat can be safely
consumed in everyday diet and be expected to improve cognitive functions and prevent
alzheimer disease.
|
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
90 |
¥Ó¥ë¥Ù¥ê¡¼¥¨¥¥¹¥Ñ¥¦¥À¡¼´ÞÍ¥µ¥×¥ê¥á¥ó¥È¤ÎÀݼè¤Ë¤è¤ë»ëµ¡Ç½²þÁ±¸ú²Ì¤Î¸¡¾Ú
|
Verification of Improve Visual Effect Function by Intake of Bilberry Extract Powder Supplement. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
89 |
¥ª¥ê¥´ÅüÊ´Ëö¤ÎÀݼè¤Ë¤è¤ëÊØÄ̲þÁ±¤Îɾ²Á¡¡¡ÝÆó½ÅÌÕ¸¡¥¯¥í¥¹¥ª¡¼¥Ð¡¼Ìµºî°Ù²½¥×¥é¥»¥ÜÈæ³Ó»î¸³¡Ý |
To evaluate the effect on bowel movements of ingesting a powdery supplement containing multiple oligosaccharides as a principal ingredient one package (5g in powder) once a day for two consecutive weeks for healthy male and female aged 20 to 59 years old who are mild constipation tendencies with 3 to 5 defecation frequency per week, a double-blind crossover randomized placebo-controlled comparative study was conducted. As a result of conducting a defecation survey (bowel movement and fecal property), improvement action of defecation amount and frequency was observed. There were no side effects or adverse events during the test period in adverse event survey, so the safety of powdery supplement containing multiple oligosaccharides as a principal ingredient was confirmed. |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
88 |
¥¢¥¹¥¿¥¥µ¥ó¥Á¥ó´ÞÍ¥«¥×¥»¥ëÀݼ褬·ò¾ïÀ®¿Í¤ÎÈ©¤ËÍ¿¤¨¤ëºîÍÑ |
30ºÐ°Ê¾å65ºÐ°Ê²¼¤Î»À²½¥¹¥È¥ì¥¹ÅÙ¤¬¹â¤¤·ò¾ïÃËÀ¤òÂоݤȤ·¤Æ¡¢ÄãÍÑÎÌ¡Ê3.57 mg¡Ë¤ËÀßÄꤷ¤¿¥¢¥¹¥¿¥¥µ¥ó¥Á¥ó´ÞÍ¥«¥×¥»¥ë¤ò4½µ´ÖϢ³Àݼ褵¤»¤¿ºÝ¤ÎÈ©¾õÂÖ¤ËÍ¿¤¨¤ëºîÍѤȰÂÁ´À¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤¹¤ë¤³¤È¤òÌÜŪ¤È¤·¤Æ¡¢Ìµºî°Ù²½Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоÈʹԷ²´ÖÈæ³Ó»î¸³¤ò¼Â»Ü¤·¡¢È©¸¡ºº¡ÊÈéÉæ¿åʬÎÌ¡¢È©²èÁü²òÀÏÁõÃ֡ˤò¹Ô¤Ã¤¿·ë²Ì¡¢Êݼ¾À¡ÊÈ©¿åʬÎ̡˵ڤÓÈ©¤Î¡Ö¤¤á¡×²þÁ±ºîÍѤ¬ÆÀ¤é¤ì¤¿¡£¤Þ¤¿¡¢Í³²»ö¾ÝÄ´ººµÚ¤ÓÎ×¾²¸¡ººÃͤˤĤ¤¤ÆÄ´¤Ù¤¿½ê¡¢»î¸³´ü´ÖÃæ¤ËÉûºîÍѵڤÓͳ²»ö¾Ý¤â¤Ê¤¯¡¢Î×¾²¸¡ººÃͤˤª¤¤¤ÆÌäÂê¤È¤Ê¤ë¤è¤¦¤ÊÊÑÆ°¤Ï¤Ê¤«¤Ã¤¿¤³¤È¤«¤é¡¢¥¢¥¹¥¿¥¥µ¥ó¥Á¥ó´ÞÍ¥«¥×¥»¥ë¤Î°ÂÁ´À¤¬³Îǧ¤µ¤ì¤¿¡£¤Ê¤ª¡¢Ëܻ¤Î¼Â»Ü¤Ë¤«¤«¤ëÈñÍѤÏÉٻΥե¤¥ë¥à³ô¼°²ñ¼Ò¤¬Ééô¤·¤¿¡£ |
Âоݼԡ¢¼çÍ×ɾ²Á¹àÌÜ¡¢Í¸úÀÀ®Ê¬ Åù |
·ÇºÜ»ï¡¢´¬¡¢¹æ Åù |
¢¥¥Ú¡¼¥¸¥È¥Ã¥× |